Loading news...
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will host an investor conference call on Thursday, February 19, 2026, at 3 p.m. Central Time.
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will host an investor conference call on Wednesday, February 18, 2026, at 3 p.m. Central Time.
Cardio Diagnostics (NASDAQ: CDIO - Get Free Report) and Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends. Volatility and Risk Cardio Diagnostics has a
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics, Aimil Ltd., and Dr. Lal PathLabs announce strategic agreement to launch Cardio Diagnostics' PrecisionCHD™ test in India.
EDINA, Minn. & CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced a partnership with the Southdale YMCA, becoming the second YMCA location nationally to partner with Cardio Diagnostics.
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced that CMS has issued a final gapfill payment rate of $854 for both the Epi+Gen CHD™ and PrecisionCHD™ tests.
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will be presenting new data at the American Heart Association (AHA) Scientific Sessions.
/PRNewswire/ -- Naples Comprehensive Health (NCH) and Caristo Diagnostics announced that NCH Rooney Heart Institute has become the first hospital in the nation
KNOXVILLE, Tenn. & CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced they are partnering with YMCA of East Tennessee to launch a customized program exclusively for its members.
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. today announced the Company has partnered with 15 new provider organizations across the United States.
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics CMS has issued preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for PrecisionCHD™.
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced an agreement with AGEPHA Pharma.
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced that the Japan Patent Office has issued a patent for another set of biomarkers in the company's IP portfolio.
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced it has regained compliance with Nasdaq minimum bid price.
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has the continued expansion of its reach with a new cohort of healthcare practices across the United States.
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings today announced a 1-for-30 reverse stock split of its common stock effective with the market opening on May 13, 2025.
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will showcase its growing portfolio of advanced cardiovascular solutions at the ACC's 74th Annual Scientific Session & Expo.
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has announced that the Company has partnered with seven new provider organizations.
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced their PrecisionCHD and Epi+Gen CHD tests have received final pricing determinations from CMS.
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics' PrecisionCHD and Epi+Gen CHD tests have received preliminary pricing determinations from CMS.